Scibase

Invest in SciBase: Pioneering Innovations in Dermatology

SciBase, a leading global medical technology company listed on Nasdaq First North Growth Market, is redefining early detection and prevention within dermatology with its advanced Nevisense platform. Built on over two decades of research from the esteemed Karolinska Institute, Nevisense leverages AI and cutting-edge Electrical Impedance Spectroscopy (EIS) technology, setting a new standard in skin health diagnostics.

Recent Achievements and Strategic Initiatives:

1. Groundbreaking Findings and Collaborations:

• Our recent case study on atopic dermatitis using Nevisense showed unprecedented improvements, positioning us to significantly enhance patient care worldwide.
• An exciting collaboration targeting early detection of atopic diseases in infants underscores our commitment to leading-edge research and development, enriching future healthcare outcomes for children globally.

2. Financial Growth and Market Expansion:

• SciBase reported a compelling 16% increase in net sales in Q3 2024, with notable growth of 187% in the US skin cancer market.
• We have secured approximately SEK 81.8 million through a strategic directed and rights issue, focusing on boosting our US operations, product development, and market penetration.

3. Clinical Excellence and Recognition:

• Nevisense has been highlighted in a US consensus report for its potential to revolutionize melanoma detection and management.
• Our alliance with the National Institutes of Health (NIH) is a testament to Nevisense's superior quality and innovation credentials, fortifying our research undertakings in skin barrier studies.

4. Strategic Corporate Moves:

• We have commenced a promising sales partnership in Italy and strengthened our position by transitioning our Certified Adviser role to Carnegie Investment Bank.
• We stay committed to expanding our footprint in the lucrative US market, infusing significant resources into sales channels across multiple regions.

SciBase invites investors to join us in our mission to revolutionize dermatological diagnostics and improve global health outcomes. Our strategic efforts aim not only at enhancing our technological capabilities but also at securing a stronghold in growing markets. With a robust plan for expansion and innovation, we are poised for sustainable long-term growth.

For more information, visit our website at www.scibase.com, or reach out to Pia Renaudin, CEO, at pia.renaudin@scibase.com.